Navigation Links
Sierra Oncology Announces Pricing of Public Offering of Common Stock
Date:2/9/2017

VANCOUVER, Feb. 9, 2017 /PRNewswire/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, today announced the pricing of an underwritten public offering of 19,500,000 shares of its common stock at a price of $1.35 per share, with expected gross proceeds to Sierra Oncology of $26.3 million. In addition, Sierra Oncology has granted the underwriters a 30-day option to purchase up to 2,925,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on February 14, 2017, subject to customary closing conditions.

Jefferies LLC is acting as the sole book-running manager for the offering. Wedbush PacGrow and SunTrust Robinson Humphrey, Inc. are acting as co-managers.

Sierra Oncology intends to use the net proceeds from the public offering to fund development of its product candidates, SRA737 and SRA141, as well as for general corporate purposes.

The securities described above are being offered by Sierra Oncology pursuant to a registration statement on Form S-3 (File No. 333-212793) that was declared effective by the Securities and Exchange Commission (SEC) on August 11, 2016. A final prospectus supplement and an accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's web site at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at 877-547-6340, or by email at prospectus_department@jefferies.com.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Sierra Oncology's intention to conduct an offering of common stock, the completion of the offering, the expected gross proceeds from the offering and the intended use of proceeds. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties, including the risk factors described under the heading "Risk Factors" set forth in Sierra Oncology's filings with the Securities and Exchange Commission from time to time, including the Company's reports filed with the Securities and Exchange Commission. Sierra Oncology undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.


'/>"/>
SOURCE Sierra Oncology
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Sierra Oncology Announces Proposed Public Offering of Common Stock
2. Sierra Wins the 2013 Laboratory Equipment Readers’ Choice Award
3. OncoSec to Present New Clinical Data from Phase 2 Combination Study at ASCO-SITC Clinical Immuno-Oncology Symposium and Corporate Updates at Two Investment Conferences in February
4. Applied BioMath, LLC and CytomX Therapeutics, Inc. announce a collaboration to develop a Quantitative Systems Pharmacology Probody platform model for use in lmmuno-Oncology
5. Jupiter Medical Center Implements Revolutionary Watson for Oncology to Help Oncologists Make Data-Driven Cancer Treatment Decisions
6. Indivumed Announces Agreement with Regeneron to Provide Tissue Samples for Oncology Research and Development
7. Applied BioMath, LLC presents work in immuno-oncology and antibody drug-conjugates at Keystone Symposium
8. Genedata Partners with Crescendo Biologics on Next-generation Immuno-oncology and ADC Programs
9. BioAtla and F1 Oncology Announce Global Collaboration to Develop Adoptive Cellular Therapies for Solid Tumors
10. Eutilex Completes $18 Million Series A Financing to Advance Immuno-Oncology Programs
11. Immuno-Oncology: A 360° View in NYC this February
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/13/2018)... Sandy Springs, GA (PRWEB) , ... November 12, ... ... cosmetic dentist with state-of-the-art practices in Alpharetta and Sandy Springs, now welcomes ... clear aligners provide a discreet and comfortable alternative to traditional braces in the ...
(Date:11/13/2018)... Ore. (PRWEB) , ... November 13, 2018 , ... ... at Bio-Logic Aqua® Research Water Life Science® in Grants Pass, Oregon believes in ... Kleyne and Bio-Logic Aqua® Research Water Life Science® sponsors the Power of Water® ...
(Date:11/9/2018)... ... November 08, 2018 , ... IC ... a machine-learning powered approach to increasing recovery rates by creating a comprehensive contact ... Collections (AIC) product developed by NLP Logix, a Jacksonville, Florida-based AI solutions company, ...
(Date:11/7/2018)... ... , ... Diversified Technologies, Inc. (DTI) has installed a PEF (Pulsed ... Technology and Innovation at ASU. Funded by a USDA NIFA SBIR, the purpose of ... and predator control applications. , Algae ponds get up to 50% consumed by predators ...
Breaking Biology Technology:
(Date:11/13/2018)... ... November 12, 2018 , ... LabRoots, ... and webinars, will be hosting its 9th Annual Clinical Diagnostics & Research ... treatments available, and updates in regulatory processes to ensure patient safety and proper ...
(Date:11/9/2018)... ... November 08, 2018 , ... Boekel Scientific launches a ... known as dry bath incubators are used in laboratories worldwide for controlling and ... the new heating blocks, Boekel Scientific used the same interface design as their ...
(Date:11/7/2018)... ... November 07, 2018 , ... CallTower, ... today a modernized and streamlined White Label Program. This enhancement delivers both a ... reseller administrative control portal. CallTower enhanced their white label program to empower resellers ...
Breaking Biology News(10 mins):